Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients of both sexes aged 3-12 years inclusively.~2. Diagnosis of influenza/ARVI according to physician's examination: body temperature ≥ 38.0°C at the time of examination + symptom score ≥ 4 (at least 1 systemic symptom ≥2 and 1 nasal/throat/chest symptom ≥2 or several symptoms ≥ 1 score).~3. The first 24 hours from the beginning of manifestations of influenza/ARVI.~4. The possibility to start therapy within 24 hours from the first symptoms of ARVI.~5. Availability of a patient information sheet (Informed Consent form) for parents/adoptive parents for participation in the study signed by one of the parents/adoptive parents.~Exclusion Criteria:~1. Suspected pneumonia, bacterial infection or severe disease requiring antibacterial products (including sulfanilamides) starting from the first day of the disease.~2. Clinical symptoms of severe influenza/ARVI requiring hospitalization.~3. Suspected initial manifestations of the diseases having the symptoms similar to the ones of influenza/ARVI (other infectious diseases, influenza-like syndrome at debut of systemic connective tissue diseases, oncohematological and other diseases).~4. Medical history of primary and secondary immunodeficiencies: а) lymphoid system immunodeficiencies (Т-cell and/or B-cell, immunodeficiencies with predominant antibody deficiency); b) phagocytic deficiencies; c) complement factor deficiency; d) combined immunodeficiencies including AIDS secondary to HIV-infection; toxic, autoimmune, infectious, radiation panleukopenic syndrome; systemic lymphocytopenic syndrome; polyclonal lymphocytic activation syndrome; postsplenectomic syndrome; congenital asplenia; immune complex pathological syndrome associated with infectious, autoimmune and allergic diseases.~5. Medical history of sarcoidosis.~6. Oncology.~7. Exacerbation or decompensation of chronic diseases affecting ability to participate in the clinical study.~8. Medical history of polyvalent allergy.~9. Allergy/intolerance to any of the components of medications used in the treatment.~10. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.~11. Intake of medicines listed in the section Prohibited concomitant therapy within 1 month prior to the inclusion in the study.~12. Drug addiction, alcohol consumption at more than 2 alcohol units per day by the subject's parents/adoptive parents.~13. Mental diseases of the subject, parents/adoptive parents.~14. Subjects whose parents/adoptive parents, according to the investigator's point of view, will not follow the observation requirements during the study or study product dosing regimen.~15. Participation in other clinical studies within 3 months prior to the inclusion in the study.~16. Parent/adoptive parent of the subject is related to the investigator team of medical facility directly involved in the study or is a close relative of the investigator. Close relatives include spouse, parents, children or brothers (sisters) regardless of whether they are biological or adoptive ones.~17. Parent/adoptive parent of the subject is working in OOO NPF Materia Medica Holding, i.e. is the company official, temporary contract worker or an appointed official responsible for the study or their close relatives.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Anaferon for Children (Type: EXPERIMENTAL): On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
- Placebo (Type: PLACEBO_COMPARATOR): On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).